摘要
目的探讨^(18)F-D3FSP正电子发射计算机断层扫描(Positron Emission Tomography/Computed Tomography,PET/CT)诊断阿尔茨海默病临床前期主观认知下降(Subject Cognitive Decline,SCD)的价值。方法纳入2021年1月至2022年12月在海南省肿瘤医院行^(18)F-D3FSP PET/CT显像的19例正常对照(Normal Control,NC)者(NC组)、42例SCD患者(SCD组)。收集研究对象的性别、年龄、受教育年限等临床特征资料,并测定全脑的^(18)F-D3FSP标准化摄取值比值(Standard Uptake Value Ratio,SUVR),应用受试者工作特征(Receiver Operating Characteristic,ROC)曲线分析全脑SUVR诊断SCD的最佳界值。比较NC组与SCD组量表评分和SUVR的差异,并通过ROC曲线分析阳性指标预测SCD的价值。结果与NC组相比,SCD组的全脑SUVR升高,差异有统计学意义(P<0.001)。受教育年限、性别、年龄和量表评分在2组间差异均无统计学意义(P>0.05)。ROC曲线显示,SUVR诊断SCD的最佳截断点为1.122,曲线下面积为0.806,敏感度为100.00%,特异性为47.37%。结论^(18)F-D3FSP PET/CT是一种敏感可靠的检测工具,在未来的临床实践中可作为SCD诊断和疾病进展评估的潜在生物标志物。
Objective To investigate the value of ^(18)F-D3FSP positron emission tomography/computed tomography(PET/CT)in diagnosing preclinical subjective cognitive decline(SCD)in Alzheimer’s disease.Methods A total of 19 normal control(NC)subjects(NC group)and 42 SCD patients(SCD group)who underwent ^(18)F-D3FSP PET/CT imaging at Hainan Cancer Hospital from January 2021 to December 2022 were enrolled.Clinical characteristics including gender,age and years of education were collected.The standard uptake value ratio(SUVR)of the whole brain was measured.The receiver operating characteristic(ROC)curve was used to analyze the optimal cutoff value of whole brain SUVR for diagnosing SCD.The scale scores and SUVR were compared between the NC group and the SCD group,and the ROC curve was applied to evaluate the predictive value of positive indicators for SCD.Results Compared with the NC group,the whole brain SUVR was higher in the SCD group,and the difference was statistically significant(P<0.001).There were no statistically significant differences in years of education,gender,age and scale scores between the two groups(P>0.05).The ROC curve showed that the optimal cutoff value of SUVR for diagnosing SCD was 1.122,with an area under the curve of 0.806,a sensitivity of 100.00%,and a specificity of 47.37%.Conclusion ^(18)F-D3FSP PET/CT is a sensitive and reliable detection tool,which can serve as a potential biomarker for the diagnosis of SCD and the assessment of disease progression in future clinical practice.
作者
孟凡盛
武冬雪
潘登
熊亮
蒋海壮
于丽娟
MENG Fansheng;WU Dongxue;PAN Deng;XIONG Liang;JIANG Haizhuang;YU Lijuan(Department of Nuclear Medicine,Hainan Cancer Hospital,Haikou Hainan 570100,China)
出处
《中国医疗设备》
2025年第6期129-133,共5页
China Medical Devices
基金
海南省自然科学基金青年基金(822QN483)
海南省肿瘤医院科研基金(2022QN04)。
作者简介
通信作者:于丽娟,主任医师,主要研究方向为疾病的多模态影像诊断。邮箱:yulijuan2003@126.com。
